
Opinion|Videos|June 11, 2024
PALOMA-3: Subcutaneous Amivantamab in Refractory EGFR-Mutated Advanced NSCLC
Expert perspectives on recent data from the PALOMA-3 study investigating subcutaneous amivantamab in patients with refractory EGFR-mutated advanced non–small cell lung cancer.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















